PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated ...

RedChip Companies aired interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, on May ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference ...

ZyVersa Therapeutics, a biopharmaceutical company ... Inflammasome inhibitor development is now at an inflection point. Major inflammasome inhibitor developers have completed their preclinical ...

Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics ... Atossa is approaching a significant inflection point in its quest to deliver best-in-class endocrine therapy ...

ORLANDO, FL / ACCESS Newswire / May 5, 2025 / RedChip Companies aired interviews with Atossa Therapeutics ... is approaching a significant inflection point in its quest to deliver best-in-class ...